Jian-Jun Liu, Sylvia Liu, Janus Lee, Huili Zheng, Resham L Gurung, Keven Ang, Huijuan Wu, Su Chi Lim
{"title":"血浆蛋白转化酶枯草杆菌素/克辛9型(PCSK9)与2型糖尿病患者慢性肾病进展的风险","authors":"Jian-Jun Liu, Sylvia Liu, Janus Lee, Huili Zheng, Resham L Gurung, Keven Ang, Huijuan Wu, Su Chi Lim","doi":"10.1111/dom.16486","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Preclinical studies have associated proprotein convertase subtilisin/kexin type 9 (PCSK9) with the pathogenesis of kidney disease. We aim to study whether plasma PCSK9 predicts the risk of chronic kidney disease (CKD) progression in patients with type 2 diabetes.</p><p><strong>Materials and methods: </strong>A total of 1902 outpatients with type 2 diabetes from a regional hospital and a primary care facility were included in this prospective study. Baseline plasma PCSK9 was measured by immunoassay. CKD progression was defined as a composite of incident end stage kidney disease (ESKD, sustained eGFR < 15 mL/min/1.73 m<sup>2</sup>, maintenance dialysis or renal death) or doubling of serum creatinine.</p><p><strong>Results: </strong>A total of 226 renal events were identified during a median of 7.2 years of follow-up. The Cox regression model showed that one standard deviation (SD) increment of plasma PCSK9 was associated with a 1.27 (95% CI 1.10-1.48) fold increased risk for the composite renal outcome after adjustment for known cardio-renal risk factors. As a categorical variable, participants with PCSK9 in the top tertile had a 1.47 (95% CI 1.02-2.12) fold adjusted risk for the renal outcome compared to those in the lowest tertile. Consistent data were obtained when ESKD was taken as the study outcome or non-renal death was taken as a competing risk.</p><p><strong>Conclusion: </strong>A high level of plasma PCSK9 is independently associated with an increased risk of CKD progression, suggesting the need to further elucidate the role of PCSK9 in diabetic kidney disease. Future studies are warranted to explore whether PCSK9 is a potential target for prevention and treatment of kidney disease.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) and the risk of chronic kidney disease progression in patients with type 2 diabetes.\",\"authors\":\"Jian-Jun Liu, Sylvia Liu, Janus Lee, Huili Zheng, Resham L Gurung, Keven Ang, Huijuan Wu, Su Chi Lim\",\"doi\":\"10.1111/dom.16486\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>Preclinical studies have associated proprotein convertase subtilisin/kexin type 9 (PCSK9) with the pathogenesis of kidney disease. We aim to study whether plasma PCSK9 predicts the risk of chronic kidney disease (CKD) progression in patients with type 2 diabetes.</p><p><strong>Materials and methods: </strong>A total of 1902 outpatients with type 2 diabetes from a regional hospital and a primary care facility were included in this prospective study. Baseline plasma PCSK9 was measured by immunoassay. CKD progression was defined as a composite of incident end stage kidney disease (ESKD, sustained eGFR < 15 mL/min/1.73 m<sup>2</sup>, maintenance dialysis or renal death) or doubling of serum creatinine.</p><p><strong>Results: </strong>A total of 226 renal events were identified during a median of 7.2 years of follow-up. The Cox regression model showed that one standard deviation (SD) increment of plasma PCSK9 was associated with a 1.27 (95% CI 1.10-1.48) fold increased risk for the composite renal outcome after adjustment for known cardio-renal risk factors. As a categorical variable, participants with PCSK9 in the top tertile had a 1.47 (95% CI 1.02-2.12) fold adjusted risk for the renal outcome compared to those in the lowest tertile. Consistent data were obtained when ESKD was taken as the study outcome or non-renal death was taken as a competing risk.</p><p><strong>Conclusion: </strong>A high level of plasma PCSK9 is independently associated with an increased risk of CKD progression, suggesting the need to further elucidate the role of PCSK9 in diabetic kidney disease. Future studies are warranted to explore whether PCSK9 is a potential target for prevention and treatment of kidney disease.</p>\",\"PeriodicalId\":158,\"journal\":{\"name\":\"Diabetes, Obesity & Metabolism\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.4000,\"publicationDate\":\"2025-05-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes, Obesity & Metabolism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/dom.16486\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/dom.16486","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
摘要
目的:临床前研究发现枯草杆菌蛋白转化酶(PCSK9)与肾脏疾病的发病机制有关。我们的目的是研究血浆PCSK9是否能预测2型糖尿病患者慢性肾脏疾病(CKD)进展的风险。材料和方法:本前瞻性研究共纳入了一家地区医院和一家初级保健机构的1902例2型糖尿病门诊患者。采用免疫分析法测定基线血浆PCSK9。CKD进展被定义为突发终末期肾病(ESKD、持续eGFR 2、维持性透析或肾性死亡)或血清肌酐翻倍的复合。结果:在中位7.2年的随访期间,共发现226例肾脏事件。Cox回归模型显示,在调整已知的心肾危险因素后,血浆PCSK9的一个标准差(SD)增加与1.27倍(95% CI 1.10-1.48)的复合肾脏结局风险增加相关。作为一个分类变量,PCSK9评分最高的受试者与最低评分的受试者相比,肾脏预后的调整风险为1.47倍(95% CI 1.02-2.12)。将ESKD作为研究结果或将非肾性死亡作为竞争风险时,获得了一致的数据。结论:高水平血浆PCSK9与CKD进展风险增加独立相关,提示有必要进一步阐明PCSK9在糖尿病肾病中的作用。未来的研究需要探索PCSK9是否是预防和治疗肾脏疾病的潜在靶点。
Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) and the risk of chronic kidney disease progression in patients with type 2 diabetes.
Aims: Preclinical studies have associated proprotein convertase subtilisin/kexin type 9 (PCSK9) with the pathogenesis of kidney disease. We aim to study whether plasma PCSK9 predicts the risk of chronic kidney disease (CKD) progression in patients with type 2 diabetes.
Materials and methods: A total of 1902 outpatients with type 2 diabetes from a regional hospital and a primary care facility were included in this prospective study. Baseline plasma PCSK9 was measured by immunoassay. CKD progression was defined as a composite of incident end stage kidney disease (ESKD, sustained eGFR < 15 mL/min/1.73 m2, maintenance dialysis or renal death) or doubling of serum creatinine.
Results: A total of 226 renal events were identified during a median of 7.2 years of follow-up. The Cox regression model showed that one standard deviation (SD) increment of plasma PCSK9 was associated with a 1.27 (95% CI 1.10-1.48) fold increased risk for the composite renal outcome after adjustment for known cardio-renal risk factors. As a categorical variable, participants with PCSK9 in the top tertile had a 1.47 (95% CI 1.02-2.12) fold adjusted risk for the renal outcome compared to those in the lowest tertile. Consistent data were obtained when ESKD was taken as the study outcome or non-renal death was taken as a competing risk.
Conclusion: A high level of plasma PCSK9 is independently associated with an increased risk of CKD progression, suggesting the need to further elucidate the role of PCSK9 in diabetic kidney disease. Future studies are warranted to explore whether PCSK9 is a potential target for prevention and treatment of kidney disease.
期刊介绍:
Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.